What has changed are 1) the market and I hope it stays that way after 1st of March. 2) Process to approval, including new Breakthrough Technology which can mean approval after what would normally be Phase 1/2a trials. 3) Well-funded NNVC, though, yes, there is the possibility of another SS88 tranche placed between now and June. 4) A product now ready for tox testing and a cGMP facility now underway.
Conditions have changed, but there will be unpredictable negative events, like the fallout and downstream effects from the pending budget sequester.
Market Data 
Markets 
AI
